Document is current

Documents that mention this clinical trial

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
https://doi.org/10.1136/jitc-2024-011427

136 A plasma proteomic based predictive biomarker for response to immunotherapy in NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0136

1229 Pre-treatment plasma proteomics-based predictive biomarkers for immune related adverse events in non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-sitc2023.1229

Documents that mention this clinical trial

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
https://doi.org/10.1136/jitc-2024-011427

Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
https://doi.org/10.1136/jitc-2021-004089

Documents that mention this clinical trial

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
https://doi.org/10.1136/jitc-2024-011427

Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
https://doi.org/10.1136/jitc-2021-002591

Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
https://doi.org/10.1136/jitc-2020-001467

Documents that mention this clinical trial

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
https://doi.org/10.1136/jitc-2024-011427

Documents that mention this clinical trial

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
https://doi.org/10.1136/jitc-2024-011427

Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer
https://doi.org/10.1136/jitc-2024-010612

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007310

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
https://doi.org/10.1136/jitc-2022-005111

Documents that mention this clinical trial

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
https://doi.org/10.1136/jitc-2024-011427

Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer
https://doi.org/10.1136/jitc-2024-010612

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
https://doi.org/10.1136/jitc-2022-005111

Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis.
https://doi.org/10.1200/jco.2024.42.16_suppl.9553

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
https://doi.org/10.1136/jitc-2021-003551

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814

816 Selective immune suppression using interleukin-6 blockade in immune related adverse events
https://doi.org/10.1136/jitc-2021-sitc2021.816

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776